{"schema":"sb.node.v1","id":"sb:e/6a74655175a14015bfeae318","kind":"entity","label":{"text":"adverse events","locale":"en"},"identity":{"anchor":"label:en:adverse events","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T21:56:07.640781+00:00","snapshot":"deploy beae7f04ec9ff24ebc8aa6d5a7712a9f42d6edf6"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":259,"separatePublishers":49,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"partial","share":0.066,"named":17,"of":259,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only","blind":["only 7% of the 259 documents measured name the subject in their own text; the rest mention it in passing, so standing.evidence.supporting overstates coverage about it"]}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-01-01","to":"2026-10-10","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.266: about 73% of mentions carry no typed assertion"]}},"dimensions":{"domains":["pubmed_targeted","pharma-regulatory"],"activeDays":50,"assertions":{"regulatory-approval":40,"election":8,"launch-release":8,"military-action":3,"price-threshold":2,"meeting-visit":2}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/c3b6e63c9a23469b0b82279f","kind":"observation","label":"Cell · 2026-09-29 · Microbiome signatures linked to cancer and treatment adverse events in a real-world cohort.","url":"https://doi.org/10.1016/j.cell.2026.09.009"},{"id":"sb:o/14381752250d1e8b96d6672b","kind":"observation","label":"Clin J Gastroenterol · 2026-09-28 · Delayed and multisystem immune-related adverse events in MSI-high colon cancer treated with nivolumab plus ipilimumab.","url":"https://doi.org/10.1007/s12328-026-02460-8"},{"id":"sb:o/69fa6b6c18e2813a07ed8c5a","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-09 · Characterizing bleeding adverse events associated with BCR-ABL tyrosine kinase inhibitors: insights from FAERS reports","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1912458"},{"id":"sb:o/59f5f49d7b237a78a199ba92","kind":"observation","label":"Gan To Kagaku Ryoho · 2026-09-01 · [Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer].","url":"https://pubmed.ncbi.nlm.nih.gov/42816176/"},{"id":"sb:o/a78f379f18fd9d7bdc85da85","kind":"observation","label":"STAT News · 2026-10-09 · STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug","url":"https://www.statnews.com/2026/10/09/biotech-news-life-biosciences-share-glaucoma-cellular-reprogramming-drug-update/?utm_campaign=rss"},{"id":"sb:o/f61c9c9d1612b3dd79ad3e21","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-29 · Case Report: Immune checkpoint inhibitor–induced hypophysitis presenting as acute paralytic ileus mimicking mechanical bowel obstruction in a patient affec…","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1934901"},{"id":"sb:o/7f12748c2e75134dfcd94359","kind":"observation","label":"The Lancet Oncology Online First · 2026-09-25 · [Articles] Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory mult…","url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00450-X/fulltext?rss=yes"},{"id":"sb:o/8652b74c979062463d7eb5db","kind":"observation","label":"Endosc Int Open · 2026-09-23 · Colorectal Endoscopic Submucosal Dissection and Acute Kidney Injury: A Rare but Clinically Relevant Adverse Event, a Cohort Study of 1537 Patients.","url":"https://doi.org/10.1055/a-2914-8234"},{"id":"sb:o/ef0659f517d1a12b988517ba","kind":"observation","label":"Surg Endosc · 2026-09-11 · Temporary interruption versus continuation of clopidogrel in patients undergoing colonoscopy with polypectomy: a systematic review and meta-analysis.","url":"https://doi.org/10.1007/s00464-026-13284-5"},{"id":"sb:o/b803fa556525a86e7c8733c4","kind":"observation","label":"FDA Drug News · 2026-08-13 · Table of Pharmacogenomic Biomarkers in Drug Labeling","url":"http://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling"}],"cursor":"c1.eyJpZCI6InNiOmUvNmE3NDY1NTE3NWExNDAxNWJmZWFlMzE4IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTEwVDIxOjU2OjA3LjY0MDc4MSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":10,"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (117 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6282db344fafb24573a1eedf"},{"kind":"relation","label":"co-mentioned with drug administration (56 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/b992eebe482fb109fccdca83"},{"kind":"relation","label":"co-mentioned with clinical trials (48 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/11a4fa1bcddd9a38c4bf53c2"},{"kind":"relation","label":"co-mentioned with immunotherapy (43 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/7cc3812c3c144a42c8e49e89"},{"kind":"relation","label":"co-mentioned with united states (41 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/de8ca76503ffaf1c5b874460"},{"kind":"relation","label":"co-mentioned with clinical trial (38 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/17dc92c86a610a2a5ac7b4a3"},{"kind":"relation","label":"co-mentioned with size (35 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/195b3957516e866884551401"},{"kind":"relation","label":"co-mentioned with colorectal cancer (30 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/0ca55f25e6e59f39ec5f42a8"},{"kind":"relation","label":"co-mentioned with lung cancer (27 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/03c5b92aa99fd7b8c507869c"},{"kind":"relation","label":"co-mentioned with medwatch (24 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/790d9a49fb545a688e461470"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/6a74655175a14015bfeae318","mcp":"traverse {\"id\":\"sb:e/6a74655175a14015bfeae318\"}","page":"/entity/adverse-events/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a74655175a14015bfeae318\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a74655175a14015bfeae318\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a74655175a14015bfeae318\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/6a74655175a14015bfeae318\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}